Total Funding
31
62
Total FundingNon-equity Assistance raised
Growth Score
-5 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
106733
Leveraging advances in computation to revolutionize the design and development of therapeutic antibodies for biopharma
- Andrew Satz: CEO
- Brett Averso: CTO
About the Company
EVQLV leverages advances in computation to revolutionize the design and development of antibody-based therapeutics, diagnostics, and reagents. EVQLV provides AI-powered de novo antibody discovery and antibody engineering to large molecule discovery scientists at biotechs, pharmaceutical companies, reagent distributors, and universities. EVQLV
strives everyday to ensure that antibodies (including VHHs, ADCs, and BsAbs) can be developed faster, cheaper, and against hard targets.
